Boston Scientific (BSX) Gains As Market Dips: What You Should Know

Boston Scientific (BSX) closed the most recent trading day at $45.60, moving +2.86% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.44%. Elsewhere, the Dow saw a downswing of 0.09%, while the tech-heavy Nasdaq depreciated by 2.22%. The stock of medical device manufacturer has fallen by 23.28% in the past month, lagging the Medical sector's gain of 0.57% and the S&P 500's gain of 0.08%.The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. In that report, analysts expect Boston Scientific to post earnings of $0.83 per share. This would mark year-over-year growth of 10.67%. Simultaneously, our latest consensus estimate expects the revenue to be $5.39 billion, showing a 6.54% escalation compared to the year-ago quarter. For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.36 per share and a revenue of $21.61 billion, signifying shifts of +9.8% and +7.65%, respectively, from the last year. Investors might also notice recent changes to analyst estimates for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.51% downward. Boston Scientific is currently sporting a Zacks Rank of #4 (Sell). Looking at valuation, Boston Scientific is presently trading at a Forward P/E ratio of 13.2. This valuation marks a discount compared to its industry average Forward P/E of 17.43. One should further note that BSX currently holds a PEG ratio of 0.85. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. BSX's industry had an average PEG ratio of 1.52 as of yesterday's close. The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 167, finds itself in the bottom 32% echelons of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks